AN2 Therapeutics, Inc. (ANTX)

NASDAQ: ANTX · Real-Time Price · USD

2.300

+0.590 (34.50%)

Mar 6, 2026, 12:21 PM EST - Market open

AN2 Therapeutics Employees

AN2 Therapeutics had 22 employees as of December 31, 2024. The number of employees decreased by 19 or -46.34% compared to the previous year.

Employees

22

Change (1Y)

-19

Growth (1Y)

-46.34%

Revenue / Employee

n/a

Profits / Employee

-$1,544,818

Market Cap

63.02M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	22	-19	-46.34%
Dec 31, 2023	41	5	13.89%
Dec 31, 2022	36	14	63.64%
Dec 31, 2021	22	-	-

Related Stocks

Company Name	Employees
Kyntra Bio	225
IGC Pharma	70
Werewolf Therapeutics	39
Lantern Pharma	24
Tempest Therapeutics	21
NeuroSense Therapeutics	17
BriaCell Therapeutics	16
Rein Therapeutics	11

Employee Rankings

ANTX News

2 days ago - AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV) - Business Wire
17 days ago - AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference - Business Wire
7 weeks ago - AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung Disease - Business Wire
4 months ago - AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights - Business Wire
4 months ago - AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB) - Business Wire
4 months ago - AN2 Therapeutics to Participate in Fireside Chat at Evercore HealthCONx Conference - Business Wire
7 months ago - AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights - Business Wire
7 months ago - AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease - Business Wire